Latest Rosiglitazone Stories
Federal health authorities are prohibiting new patients from enrolling in a safety study for GlaxoSmithKlineâ€™s controversial diabetes pill Avandia, a week after an expert panel ruled that the drug increases heart risks.
The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone.
A panel of US Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill.
DALLAS, July 14 /PRNewswire-USNewswire/ -- After two days of hearings, an advisory committee to the U.S.
DEERFIELD, Ill., July 14 /PRNewswire/ -- The U.S.
PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market.
GlaxoSmithKline Plc stood up for its diabetes pill Avandia against US advisers this week, claiming that it was safe and should stay on the market.
The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.
Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio.
New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone.
- To give a box on the ear to.